Literature DB >> 26718225

EGFR/MDM2 signaling promotes NF-κB activation via PPARγ degradation.

Ying Xu1,2,3, Jianhua Jin4, Wenbo Zhang2,5, Zhi Zhang6, Jiaming Gao6, Qian Liu4, Chenglin Zhou7, Qinggang Xu4, Haifeng Shi4, Yongzhong Hou1,2, Juanjuan Shi6.   

Abstract

Dysregulated expression of epidermal growth factor receptor (EGFR) has been implicated in many cancer events, while peroxisome proliferator-activated receptor γ (PPARγ) negatively regulates cancer progression. The molecular mechanism of EGFR interaction with PPARγ is still unclear. Here, we found that nuclear EGFR induced phosphorylation of PPARγ at Tyr-74 leading to PPARγ ubiquitination and degradation by mouse double minute 2 (MDM2) ubiquitin ligase. PPARγ degradation by EGFR/MDM2 signaling resulted in accumulation of nuclear factor-kappaB (NF-κB)/p65 protein levels and increasing NF-κB activation. In contrast, PPARγ-Y74A mutant reversed this event. Moreover, PPARγ-Y74A mutant suppressed cell proliferation and increased chemotherapeutic agent-induced cancer cell sensitivity. Importantly, the clinical findings show that the nuclear phosphorylation of PPARγ-Y74 and EGFR expression in colonic cancer tissues was higher than that in control normal tissues. Thus, our study revealed a novel molecular mechanism that nuclear EGFR/NF-κB signaling promoted cell proliferation by destructing PPARγ function, which provides a novel strategy for cancer treatment. © Crown copyright 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26718225     DOI: 10.1093/carcin/bgv252

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

1.  Sonic hedgehog signaling instigates high-fat diet-induced insulin resistance by targeting PPARγ stability.

Authors:  Qinyu Yao; Jia Liu; Lei Xiao; Nanping Wang
Journal:  J Biol Chem       Date:  2018-12-20       Impact factor: 5.157

2.  PPARδ is a regulator of autophagy by its phosphorylation.

Authors:  Qian Gou; Yidan Jiang; Runyun Zhang; Ying Xu; Huihui Xu; Wenbo Zhang; Juanjuan Shi; Yongzhong Hou
Journal:  Oncogene       Date:  2020-05-21       Impact factor: 9.867

Review 3.  Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy.

Authors:  Qian Gou; Xin Gong; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  Oncotarget       Date:  2017-07-27

4.  The E3 ubiquitin ligase TRIM25 regulates adipocyte differentiation via proteasome-mediated degradation of PPARγ.

Authors:  Jae Min Lee; Sun Sil Choi; Yo Han Lee; Keon Woo Khim; Sora Yoon; Byung-Gyu Kim; Dougu Nam; Pann-Ghill Suh; Kyungjae Myung; Jang Hyun Choi
Journal:  Exp Mol Med       Date:  2018-10-15       Impact factor: 8.718

Review 5.  The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors.

Authors:  Helei Hou; Dantong Sun; Xiaochun Zhang
Journal:  Cancer Cell Int       Date:  2019-08-22       Impact factor: 5.722

6.  LncRNA SNHG1 Facilitates Tumor Proliferation and Represses Apoptosis by Regulating PPARγ Ubiquitination in Bladder Cancer.

Authors:  Hongzhou Cai; Haifei Xu; Hongcheng Lu; Weizhang Xu; Haofeng Liu; Xinwei Wang; Guoren Zhou; Xuejian Yang
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

Review 7.  The Involvement of PPARs in the Peculiar Energetic Metabolism of Tumor Cells.

Authors:  Andrea Antonosante; Michele d'Angelo; Vanessa Castelli; Mariano Catanesi; Dalila Iannotta; Antonio Giordano; Rodolfo Ippoliti; Elisabetta Benedetti; Annamaria Cimini
Journal:  Int J Mol Sci       Date:  2018-06-29       Impact factor: 5.923

8.  Antitumor Effects and the Compatibility Mechanisms of Herb Pair Scleromitrion diffusum (Willd.) R. J. Wang-Sculellaria barbata D. Don.

Authors:  Li Lu; Sheng Zhan; Xiaohui Liu; Xin Zhao; Xiukun Lin; Huanli Xu
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.